Lyell Immunopharma Q3 2026 Earnings Date & Estimates

Lyell Immunopharma (NASDAQ:LYEL) is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell’s research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy. Its pipeline includes investigational cell therapy candidates targeting cancer-associated antigens, with development focused primarily on solid tumors. These candidates remain under clinical evaluation and are not approved for commercial use.

Founded in 2018, Lyell Immunopharma is headquartered in South San Francisco, California. The company’s work is supported by research, clinical development, and manufacturing operations intended to advance engineered T-cell therapies for patients with difficult-to-treat cancers. Lynn Seely serves as the company’s president and chief executive officer.